Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Nemolizumab Auto-Injector vs Dual-Chamber Syringe
NCT05405985Phase 1Completed
- Sponsor
- Galderma
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nemolizumab in atopic dermatitis (AD) and prurigo nodularis (PN) (2 arms), sponsored by Galderma. Primary endpoints: Maximum Observed Plasma Concentration and Area Under Concentration-time Curve Extrapolated to Infinity. Started Aug 2022; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT05405985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405985.